Diabetes and Atherothrombotic Disease: Linked through Inflammation?

Russell P. Tracy

doi:10.1055/s-2002-23097

Seminars in Vascular Medicine, Table of Contents

Semin Vasc Med 2002; 2(1): 067-074
DOI: 10.1055/s-2002-23097

Diabetes and Atherothrombotic Disease: Linked through Inflammation?

Russell P. Tracy

Department of Pathology and Biochemistry, College of Medicine, University of Vermont, Colchester, Vermont

Abstract

ABSTRACT

Inflammation has been accepted as a key pathobiological mechanism in the development of cardiovascular disease, and acceptance is likely on its way for diabetes as well. Inflammation provides a linking mechanism between these two disorders, allowing them to influence each other in a wide variety of ways. Interventions aimed broadly at inflammation are likely to influence both diseases, and pathway-specific interventions may prove useful as well. The role of genetic variation remains poorly understood.

KEYWORD

Diabetes - insulin resistance - obesity - inflammation - thrombosis

Full Text

References

REFERENCES

1 Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med . 1999; 340 115-126
2 Virchow R. Die Cellularpathologie in ihrer Begründung auf physiologische und pathologische Gewebelehre. Berlin 1858
3 Ross R. The pathogenesis of atherosclerosis-an update. N Engl J Med . 1986; 314 488-500
4 Meade T, Brozovic M, Chakrabarti R. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet . 1986; 2 533-537
5 Kannel W, Wolf P, Castelli W, D'Agostino R. Fibrinogen and risk of cardiovascular disease: the Framingham study. JAMA . 1987; 258 1183-1186
6 Stone M, Thorp J. Plasma fibrinogen-a major coronary risk factor. J R Coll Gen Pract . 1985; 35 565-569
7 Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med . 1984; 311 501-505
8 Yarnell J, Baker I, Sweetnam P. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. Circulation . 1991; 83 836-844
9 Tracy R P, Arnold A M, Ettinger W, Fried L, Meilahn E, Savage P. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol . 1999; 19 1776-1783
10 Folsom A R, Wu K K, Rosamond W D, Sharrett A R, Chambless L E. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation . 1997; 96 1102-1108
11 Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA . 1998; 279 1477-1482
12 Kuller L, Eichner J, Orchard T, Grandits G, McCallum L, Tracy R, for the MRFIT Research Group. The relation between serum albumin levels and risk of coronary heart disease in the Multiple Risk Factor Intervention Trial. Am J Epidemiol . 1991; 134 1266-1277
13 Koenig W, Sund M, Frohlich M. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Circulation . 1999; 99 237-242
14 Liuzzo G, Biasucci L, Gallimore J. The prognostic value of C-reactive protein and serum amyloid. A protein in severe unstable angina. N Engl J Med . 1994; 331 417-424
15 Bataille R, Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo [letter]. Arthritis Rheum . 1992; 35 982-984
16 Thompson S, Kienast J, Pyke S, Haverkate F, van de Loo J. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med . 1995; 332 635-641
17 Kuller L, Tracy R, Shaten J, Meilahn E, for the MRFIT Research Group. Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol . 1996; 144 537-547
18 Tracy R, Lemaitre R, Psaty B. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol . 1997; 17 1121-1127
19 Cushman M, Arnold A, Kuller L. C-reactive protein and risks of myocardial infarction, stroke and death in an elderly cohort [abstract]. Circulation . 1999; 98 1108
20 Ridker P, Cushman M, Stampfer M, Tracy R, Hennekens C. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med . 1997; 336 973-979
21 Ridker P M, Buring J E, Shih J, Matias M, Hennekens C H. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation . 1998; 98 731-733
22 Ridker P M, Glynn R J, Hennekens C H. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation . 1998; 97 2007-2011
23 Mendall M A, Patel P, Ballam L, Strachan D, Northfield T C. C-reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ . 1996; 312 1061-1065
24 Tracy R, Macy E, Bovill E. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol . 1997; 17 2167-2176
25 Yudkin J S, Stehouwer C D, Emeis J J, Coppack S W. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol . 1999; 19 972-978
26 Aggawal B, Puri R, eds.. Human Cytokines: Their Role in Disease and Therapy Cambridge, MA: Blackwell Science 1995
27 Levi M, ten Cate H, van der Poll T, van Deventer J. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA . 1993; 270 975-979
28 Esmon C, Taylor F, Snow T. Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemostas . 1991; 66 160-165
29 Tracy R. Atherosclerosis, thrombosis and inflammation: a question of linkage. Fibrinolysis and Proteolysis . 1997; 11 (suppl 1) 137-142
30 Festa A, D'Agostino Jr R, Howard G, Mykkanen L, Tracy R P, Haffner S M. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation . 2000; 102 42-47
31 Ridker P M, Rifai N, Stampfer M J, Hennekens C H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation . 2000; 101 1767-1772
32 Harris T B, Ferrucci L, Tracy R P. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med . 1999; 106 506-512
33 Ridker P M, Hennekens C H, Buring J E, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med . 2000; 342 836-843
34 Ernst E, Resch K. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann Intern Med . 1993; 118 956-963
35 Tracy R P. Inflammation in cardiovascular disease: cart, horse, or both?. Circulation . 1998; 97 2000-2002
36 Melnick S L, Shahar E, Folsom A R. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Am J Med . 1993; 95 499-504
37 Howell T H, Ridker P M, Ajani U A, Hennekens C H, Christen W G. Periodontal disease and risk of subsequent cardiovascular disease in U.S male physicians. J Am Coll Cardiol . 2001; 37 445-450
38 Folsom A R, Nieto F J, Sorlie P, Chambless L E, Graham D Y. Helicobacter pylori seropositivity and coronary heart disease incidence. Atherosclerosis Risk In Communities (ARIC) Study Investigators. Circulation . 1998; 98 845-850
39 Davidson M, Kuo C C, Middaugh J P. Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation . 1998; 98 628-633
40 Nieto F. Infections and atherosclerosis: new clues from an old hypothesis?. Am J Epidemiol . 1998; 148 937-948
41 Nieto F J, Folsom A R, Sorlie P D, Grayston J T, Wang S P, Chambless L E. Chlamydia pneumoniae infection and incident coronary heart disease: the Atherosclerosis Risk in Communities Study. Am J Epidemiol . 1999; 150 149-156
42 Tracy R P. Inflammation markers and coronary heart disease. Curr Opin Lipidol . 1999; 10 435-441
43 Tracy R, Bovill E, Yanez D, for the CHS Investigators. Fibrinogen and factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly: results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol . 1995; 15 1269-1279
44 Lagrand W K, Visser C A, Hermens W T. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?. Circulation . 1999; 100 96-102
45 Cermak J, Key N, Bach R, Balla J, Jacob H, Vercellotti G. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood . 1993; 82 513-520
46 Pasceri V, Willerson J T, Yeh E T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation . 2000; 102 2165-2168
47 Ridker P M, Rifai N, Pfeffer M A. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation . 1998; 98 839-844
48 Ridker P M, Rifai N, Pfeffer M A, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation . 1999; 100 230-235
49 Ridker P M, Rifai N, Clearfield M. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med . 2001; 344 1959-1965
50 Cushman M, Meilahn E N, Psaty B M, Kuller L H, Dobs A S, Tracy R P. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol . 1999; 19 893-899
51 Cushman M, Legault C, Barrett-Connor E. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation . 1999; 100 717-722
52 Walsh B W, Paul S, Wild R A. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab . 2000; 85 214-218
53 Cushman M, Costantino J P, Tracy R P. Tamoxifen and cardiac risk factors in healthy women: suggestion of an anti-inflammatory effect. Arterioscler Thromb Vasc Biol . 2001; 21 255-261
54 de Maat P M, Kastelein J J, Jukema J W. -455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group. Arterioscler Thromb Vasc Biol . 1998; 18 265-271
55 Schmidt H, Schmidt R, Niederkorn K. Beta-fibrinogen gene polymorphism (C148T) is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. Arterioscler Thromb Vasc Biol . 1998; 18 487-492
55a Humphries S E, Luong L A, Ogg M S, Hawe E, Miller G C. The interleukin-6-174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J . 2001; 22 2243-2252
56 Ogg M, Tracy R, Luong L. The -174 G/C interleukin-6 polymorphism is associated with increased levels of inflammation markers and increased blood pressure [abstract]. Circulation . 2000; 101 712
57 Huber S A, Sakkinen P, Conze D, Hardin N, Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol . 1999; 19 2364-1367
58 Huber S A, Sakkinen P, David C, Newell M K, Tracy R P. T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia. Circulation . 2001; 103 2610-2616
59 Schmidt M I, Duncan B B, Sharrett A R. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet . 1999; 353 1649-1652
60 Festa A, D'Agostino Jr R, Tracy R, Haffner S. Elevated levels of acute phase proteins predict the development of type 2 diabetes mellitus-The Insulin Resistance Atherosclerosis Study (IRAS) [abstract]. Diabetes . 2000; 49 (suppl 1) A24
61 Sakkinen P A, Wahl P, Cushman M, Lewis M R, Tracy R P. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol . 2000; 152 897-907
62 Meigs J, D'Agostino R, Wilson P, Cupples L, Nathan D, Singer D. Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes . 1997; 46 1594-1600
63 Edwards K L, Austin M A, Newman B, Mayer E, Krauss R M, Selby J V. Multivariate analysis of the insulin resistance syndrome in women. Arterioscler Thromb Vasc Biol . 1994; 14 1940-1945
64 Tracy R, Losito R, Howard P, Cushman M, Bovill E. The association of plasma lipids and vitamin K-dependent coagulation factors. In: Bray G, Ryan D, eds. Nutrition, Genetics and Heart Disease Baton Rouge, LA: LSU Pr 1996: 29-49
65 Hoffman C, Lawson W, Miller R, Hultin M. Correlation of vitamin K-dependent clotting factors with cholesterol and triglycerides in healthy young adults. Arterioscler Thromb Vasc Biol . 1994; 14 1737-1740
66 Alessi M, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor-1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes . 1997; 46 860-867
67 Kluft C, Verheijen J, Jie A. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast actimg inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest . 1985; 45 605-610
68 Vague P, Juhan-Vague I, Aillaud M. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism . 1986; 35 250-253
69 Alessi M, Juhan-Vague I, Kooistra T, Declerck P, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor-1 by the human hepatocellular cell line HepG2. Thromb Haemostas . 1988; 60 491-494
70 Kooistra T, Bosma P, Tons H, van den Berg A, Meyer P, Princen H. Plasminogen activator inhibitor-1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemostas . 1989; 62 723-728
71 Grant P, Kruithof E, Felley C, Felber J, Bachmann F. Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man. Clin Sci . 1990; 79 513-516
72 Sobel B E. Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox [editorial]. Circulation . 1999; 99 2496-2498
73 Iacoviello L, Di Castelnuovo A, De Knijff P. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med . 1998; 338 79-85
74 Iacoviello L, Burzotta F, Di Castelnuovo A, Zito F, Marchioli R, Donati M B. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis [letter]. Thromb Haemost . 1998; 80 1029-1030
75 Corral J, Gonzalez-Conejero R, Lozano M, Rivera J, Heras I, Vicente V. The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial disease. Br J Haemotol . 1997; 99 304-307
76 Bertina R, Koeleman B, Koster T. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature . 1994; 369 64-67
77 Kalafatis M, Mann K. Factor V_Leiden and thrombophilia. Arterioscler Thromb Vasc Biol . 1997; 17 620-627
78 Cushman M, Rosendaal F R, Psaty B M. Factor VLeiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study. Thromb Haemost . 1998; 79 912-915
79 Rosendaal F R, Siscovick D S, Schwartz S M. Factor V_Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood . 1997; 89 2817-2821
80 Sakkinen P A, Cushman M, Psaty B M. Correlates of antithrombin, protein C, protein S, and TFPI in a healthy elderly cohort. Thromb Haemost . 1998; 80 134-139
81 Jacobs J, Tracy R, Gross M. Plasma C-reactive protein and vitamin C are associated with coronary calcification in young adults: The Cardia Study [abstract]. Circulation . 2000; 101 720
82 Ridker P, Hennekens C, Cerskus A, Stampfer M. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation . 1994; 90 2236-2240
83 Folsom A R, Aleksic N, Park E, Salomaa V, Juneja H, Wu K K. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol . 2001; 21 611-617
84 Lowe G D, Rumley A. Use of fibrinogen and fibrin D-dimer in prediction of arterial thrombotic events. Thromb Haemost . 1999; 82 667-672
85 Cushman M, Lemaitre R N, Kuller L H. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol . 1999; 19 493-498
86 Kohler H P, Stickland M H, Ossei-Gerning N, Carter A, Mikkola H, Grant P J. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost . 1998; 79 8-13
87 Weiss E J, Bray P F, Tayback M. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med . 1996; 334 1090-1094
88 Ridker P, Hennekens C, Schmitz C, Stampfer M, Lindpaintner K. PI A1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet . 1997; 349 385-388
89 Cheung A T, Ree D, Kolls J K, Fuselier J, Coy D H, Bryer-Ash M. An in vivo model for elucidation of the mechanism of tumor necrosis factor-alpha (TNF-alpha)-induced insulin resistance: evidence for differential regulation of insulin signaling by TNF-alpha. Endocrinology . 1998; 139 4928-4935
90 Scarim A L, Heitmeier M R, Corbett J A. Irreversible inhibition of metabolic function and islet destruction after a 36-hour exposure to interleukin-1beta. Endocrinology . 1997; 138 5301-5307